$323,800–$399,900
USD/year
This role focuses on the rare bone disease franchise, specifically preparing for the potential commercialization of a monoclonal antibody therapy for Osteogenesis Imperfecta (OI) and supporting Crysvita for XLH. Reporting to the VP Global/US Medical Affairs and Strategy, the Executive Director will establish partnerships with key opinion leaders, lead scientific education, and provide strategic medical expertise to the program and commercialization teams.